Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
August 1, 2017 4:05 PM EDTCommercial & Financial Highlights
Revenue of $35.6 million in second quarter 2017, an increase of 80 percent from second quarter 2016 2017 revenue guidance increased by $20 million, to $145-155 millionGAAP net income of $0.10 per share, compared to $0.01 per share in second quarter 2016Non-GAAP net income of $0.13 per share, compared to $0.03 per share in second quarter 2016Final payment made in July 2017 on capped royalty financing obligationÂClinical Highlights
Enrollment continues in Phase 2, open-label trial of CORT125134... More